Linked Life Data

1661121

Source:http://linkedlifedata.com/resource/pubmed/id/1661121

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1992-1-29
pubmed:abstractText
The efficacy and safety of a low molecular weight heparin (LMWH) given as a single predialysis bolus injection was compared to standard heparin (SH) administered with a continuous infusion in a randomized, 6 month, open follow-up study in 70 patients undergoing hemodialysis. No major bleeding or adverse events were encountered during a total of 4,000 dialysis procedures (2,000 with LMWH). Clot formation in the extracorporeal circuit was minimal and comparable between the groups at 4, 13, and 26 weeks after the start of the study. No accumulation of LMWH anticoagulant activity was noted. It is concluded that the use of LMWH is a safe, effective, and less complex alternative to SH.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0889-7190
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
M459-61
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin.
pubmed:affiliation
Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, Amsterdam, The Netherlands.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial